Authors' response: "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group".
作者信息
Agarwal Manisha, Muralidhar Alankrita, Chakraborty Debdulal, Shanmugam Mahesh P
机构信息
Department of Vitreoretina and Uvea, Dr Shroff's Charity Eye Hospital, New Delhi, India.
Department of Vitreoretina and Uvea, Vivekananda Nethralaya, Dehradun, Uttarakhand, India.
出版信息
Indian J Ophthalmol. 2025 Jun 1;73(6):926-927. doi: 10.4103/IJO.IJO_2773_24. Epub 2025 May 28.
Abstract
摘要
相似文献
1
Authors' response: "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group".作者回复：“VRSI研究组关于印度患者中布罗利尤单抗相关的眼内炎症”
Indian J Ophthalmol. 2025 Jun 1;73(6):926-927. doi: 10.4103/IJO.IJO_2773_24. Epub 2025 May 28.
2
Comment on "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group".对“VRSI研究组关于印度患者中布罗鲁单抗相关眼内炎症”的评论
Indian J Ophthalmol. 2025 Jun 1;73(6):925-926. doi: 10.4103/IJO.IJO_2590_24. Epub 2025 May 28.
3
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.由 VRSI 研究小组报告的印度患者中与 brolucizumab 相关的眼内炎症。
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
4
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.印度眼中 Brolucizumab 治疗后眼内炎症的发生率、临床特征、危险因素和结局：一项多中心研究。
Indian J Ophthalmol. 2023 May;71(5):1979-1985. doi: 10.4103/IJO.IJO_2688_22.
5
Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.玻璃体内注射布罗鲁单抗后发生眼内炎的患者再次注射情况。
Korean J Ophthalmol. 2025 Jun;39(3):213-221. doi: 10.3341/kjo.2024.0125. Epub 2025 Apr 16.
6
[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy].使用布罗利珠单抗时的眼内炎症：患者管理-诊断-治疗
Ophthalmologe. 2021 Mar;118(3):248-256. doi: 10.1007/s00347-021-01321-8. Epub 2021 Feb 8.
7
Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.经 Tenon 囊下注射曲安奈德预防与 brolucizumab 相关的眼内炎症。
Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2529-2535. doi: 10.1007/s00417-022-05611-y. Epub 2022 Mar 2.
8
Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.在印度真实世界场景中，布罗利珠单抗与阿柏西普治疗顽固性糖尿病性黄斑水肿的比较——BRADIR研究
Am J Ophthalmol Case Rep. 2024 Aug 23;36:102152. doi: 10.1016/j.ajoc.2024.102152. eCollection 2024 Dec.
9
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India.布罗利珠单抗治疗新生血管性年龄相关性黄斑变性患者的安全性和有效性：一项来自印度的IV期研究。
Indian J Ophthalmol. 2025 Jun 1;73(6):826-832. doi: 10.4103/IJO.IJO_1914_24. Epub 2025 Apr 17.
10
Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.Brolucizumab 治疗后伴眼内炎症的眼的临床特征和结局：HAWK 和 HARRIER 的事后分析。
Ophthalmol Retina. 2022 Feb;6(2):97-108. doi: 10.1016/j.oret.2021.05.003. Epub 2021 May 8.
本文引用的文献
1
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.由 VRSI 研究小组报告的印度患者中与 brolucizumab 相关的眼内炎症。
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
2
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.印度眼中 Brolucizumab 治疗后眼内炎症的发生率、临床特征、危险因素和结局：一项多中心研究。
Indian J Ophthalmol. 2023 May;71(5):1979-1985. doi: 10.4103/IJO.IJO_2688_22.
Zotero 插件